| No. 37 |
Trends in Biopharmaceutical Alliances for the Key Business Models
Bruce Rasmussen, December 2007
|
| No. 36 |
Trends and Outcomes in the Australian Pharmaceutical Benefits Scheme
Kim Sweeny, December 2007
|
| No. 35 |
Key Aspects of the Australian Pharmaceutical Benefits Scheme
Kim Sweeny, November 2007
|
| No. 34 |
The Pharmaceutical Industry in Australia
Kim Sweeny, September 2007
|
| No. 33 |
Response of Pharmaceutical Companies to Biotechnology: Structure and
Business Models
Bruce Rasmussen, August 2007
|
| No. 32 |
Business Models and the Theory of the Firm
Bruce Rasmussen, June 2007
|
| No. 31 |
Open Innovation and the Networked Firm
Bruce Rasmussen, May 2007
|
| No. 30 |
Is Europe a
laggard in pharmaceuticals? R&D joint ventures, patent quality and
R&D productivity
George Messinis, September 2005 |
| |
|
| No. 29 |
Medicine prices in
Australia: An international comparison
Kim Sweeny, September 2005 |
| |
|
| No. 28 |
Accounting for
growth in the Pharmaceutical Benefits Scheme (superseded by PIP
Working Papers No. 34 to 36 – see above)
Kim Sweeny, September
2005 |
| |
|
| No.27 |
Patent
Quality
and R&D Productivity in Pharmaceuticals: The Role of Inflation and
International Collaboration’
George Messinis, August 2005 |
| |
|
| No. 26 |
Cost benefit
analysis of the PBS program: A new approach
Christine Mak and
Sardar Islam, May 2005 |
| |
|
| No. 25 |
A new framework
for cost benefit analysis of the health programs: A social choice
approach
Christine Mak and Sardar Islam, April 2005 |
| |
|
| No. 24 |
Developing the Biomedical Industries in Canada and Australia: An
Innovation Systems Approach
Bruce Rasmussen, February 2005 |
| |
|
| No. 23 |
Alliance Opportunities for Aus Biotech
Bruce Rasmussen, April 2004 |
| |
|
| No. 22 |
The Biomedical Sectors in Australia and Canada: Comparative Policy Analysis,
Bruce Rasmussen, July 2004 |
| |
|
| No. 21 |
An Analysis of the Biomedical Sectors in Australia and Canada in a National Innovation Systems Context
Bruce Rasmussen, July 2004 |
| |
|
| No. 20 |
The Biomedical Sectors in Australia and Canada: A Comparative Analysis
Bruce Rasmussen, May 2004 |
| |
|
| No. 19 |
Review of Findings: Australian Pharmaceutical Pricing in a Global Context
(superseded by PIP Working Paper No. 29 – see above)
Kim Sweeny, April 2004 |
| |
|
| No. 18 |
R&D Price Inflation, Real BERD and Innovation: Pharmaceuticals, OECD 1980-2000
George Messinis, May 2004 |
| |
|
| No. 17 |
Innovation and Industry Structure in the Biomedical Industry: Some Preliminary Results
Bruce Rasmussen, February 2004 |
| |
|
| No. 16 |
Australian Pharmaceutical Pricing in a Global Context: Trends and Issues
Kim Sweeny, February 2004 |
| |
|
| No. 15 |
Aspects of the Pharmaceutical Business Model: Implications for Australia
Bruce Rasmussen, August 2003 |
| |
|
| No. 14 |
Price and Quantity Trends in the Pharmaceutical Benefits Scheme
Kim Sweeny, August 2003 |
| |
|
| No. 13 |
Pharmaceuticals, Health and Industry Development: Strategic Issues and Options,
Peter Sheehan, August 2002 |
| |
|
| No. 12 |
Competition and Drug Pricing in the PBS: An Economic Interpretation
Peter Sheehan and Kim Sweeny, August 2002 |
| |
|
| No. 11 |
Demand and Price Dynamics in International Market: Some Preliminary Results
Kim Sweeny, August 2002 |
| |
|
| No. 10 |
Generic Drugs: International Trends and Policy Developments in Australia
Hans Lofgren, August 2002 |
| |
|
| No. 9 |
Health Costs, Innovation and Ageing
Peter Sheehan, August 2002 |
| |
|
| No. 8 |
Development Paths for Australian Biomedical Firms
Bruce Rasmussen and
Kim Sweeny, September 2002 |
| |
|
| No. 7 |
The Australian Pharmaceutical Industry and Its Global Context
George Messinis,
September 2002 |
| |
|
| No. 6 |
Demand and Price Dynamics within the Pharmaceutical Benefits Scheme
Kim Sweeny,
June 2002 |
| |
|
| No. 5 |
Trends in the Use and Cost of Pharmaceuticals under the Pharmaceutical Benefits Scheme
Kim Sweeny, June 2002 |
| |
|
| No. 4 |
Information Technology and the Revolution in Healthcare
John Houghton, June 2002 |
| |
|
| No. 3 |
Technology Trends in Drug Discovery and Development: Implications for the Development of the Pharmaceutical Industry in Australia
Kim Sweeny, March 2002 |
| |
|
| No. 2 |
The Role of Pharmaceutical Alliances
Bruce Rasmussen, June 2002 |
| |
|
| No. 1 |
Implications of the Business Strategies of Pharmaceutical Companies for Industry Developments in Australia
Bruce Rasmussen, March 2002 |
